secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quanterix Corp (QTRX)
CIK:        0001503274
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001503274-25-000004
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quanterix to acquire Akoya Biosciences; expands addressable market to $5B
-------------------------------------------------------------------------

- Transaction expected to close in Q2 2025; combined cash at close ~$175M.
- Combined installed base of 2,300+ instruments; addressable market grows from $1B to $5B.
- Expands Quanterix from neurology into oncology and immunology via Akoya's tissue biomarker platform.
- Post-closing, combined company will operate under Quanterix name; integration team being formed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503274/000150327425000004/0001503274-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503274/000150327425000004/qtrx-20250110.htm
  HTML page:      https://secwatch.observer/filing/0001503274-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer